Mr. Bonsal was a founding member of Red Abbey Venture Partners. Mr. Bonsal was also a founding partner of New Enterprise Associates (NEA), one of the country’s largest venture capital firms. During his tenure at NEA, Mr. Bonsal served on the Board of Directors of a number of life sciences companies, including Aspect Medical Systems, Inc. (NASDAQ: ASPM), Biopure Corporation (NASDAQ: BPUR), Cantab Pharmaceuticals PLC (acquired by Xenova Group PLC), GeneScreen, Inc. (acquired by Orchid Biosciences, Inc.), IBAH, Inc. (acquired by Omnicare, Inc.), Molecular Tool, Inc. (acquired by Orchid Biosciences, Inc.), Synaptic Pharmaceuticals Corporation (acquired by H. Lundbeck A/S), and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX). Additionally, Mr. Bonsal played an active role in a number of NEA’s life sciences investments, including Alkermes, Inc. (NASDAQ: ALKS), Anadys Pharmaceuticals, Inc., Bethesda Research Laboratories, Inc. (acquired by Life Technologies, Inc.), Dura Pharmaceuticals, Inc. (acquired by Elan Corporation), GelTex Pharmaceuticals, Inc. (acquired by Genzyme General), Genetic Therapy, Inc. (acquired by Sandoz), Pyxis Corporation (acquired by Cardinal Health, Inc.) and Sepracor, Inc. (NASDAQ: SEPR).
Mr. Bonsal has been a key investor and advisor in a number of venture capital firms during his career, including Amadeus Capital Partners, Boulder Ventures, Novak Biddle Venture Partners, Sterling Venture Partners, Trellis Ventures, Venturehouse and Windward Ventures.
Mr. Bonsal is a member of the Board of Trustees of the Johns Hopkins Hospital and a member of the Johns Hopkins Hospital Endowment Board. Also, Mr. Bonsal serves on the Board of Directors of a technology company, Ceratech, as well as an investment advisory firm, Brown Investment Advisory and Trust Co.
Prior to co-founding NEA in 1978, Mr. Bonsal was a General Partner of Alex. Brown & Sons, Inc. Mr. Bonsal received a BA in Economics from Princeton University in 1959.